key: cord-0873643-ulvlsqch
authors: Stirrup, Oliver; Krutikov, Maria; Tut, Gokhan; Palmer, Tom; Bone, David; Bruton, Rachel; Fuller, Chris; Azmi, Borscha; Lancaster, Tara; Sylla, Panagiota; Kaur, Nayandeep; Spalkova, Eliska; Bentley, Christopher; Amin, Umayr; Jadir, Azar; Hulme, Samuel; Giddings, Rebecca; Nacer-Laidi, Hadjer; Baynton, Verity; Irwin-Singer, Aidan; Hayward, Andrew; Moss, Paul; Copas, Andrew; Shallcross, Laura
title: SARS-CoV-2 anti-spike antibody levels following second dose of ChAdOx1 nCov-19 or BNT162b2 in residents of long-term care facilities in England (VIVALDI)
date: 2022-04-16
journal: J Infect Dis
DOI: 10.1093/infdis/jiac146
sha: 1207c06ce16498c7e975e6fe5934f49931caac93
doc_id: 873643
cord_uid: ulvlsqch

General population studies have shown strong humoral response following SARS-CoV-2 vaccination with subsequent waning of anti-spike antibody levels. Vaccine-induced immune responses are often attenuated in frail and older populations, but published data are scarce. We measured SARS-CoV-2 anti-spike antibody levels in Long-Term Care Facility residents and staff following second vaccination dose with Oxford-AstraZeneca or Pfizer-BioNTech. Vaccination elicited robust antibody responses in older residents, suggesting comparable levels of vaccine-induced immunity to that in the general population. Antibody levels are higher after Pfizer-BioNTech vaccination but fall more rapidly compared to Oxford-AstraZeneca recipients and are enhanced by prior infection in both groups.

Residents of Long-Term Care Facilities (LTCF) have experienced extremely high rates of SARS-CoV-2 2 infection and mortality [1] . Since December 2020, LTCF staff and residents in England have been 3 prioritised for vaccination against SARS-CoV-2, with initial roll-out primarily using the mRNA-based 4

BNT162b2 (Pfizer-BioNTech) and adenoviral vector-based ChAdOx1 (Oxford-AstraZeneca) vaccines [2] . 5

Vaccine effectiveness in the general population has been demonstrated for at least six months following 6 second dose administration [3, 4] . However, data are limited on the duration and magnitude of 7 protection afforded by vaccination in LTCF residents. Furthermore, LTCF residents are especially 8 vulnerable to severe outcomes following infection due to frailty, high rates of co-morbidity, poorer 9 nutritional status, and age-related dampening of immune responses (immune-senescence) which impact 10 on vaccine-induced immunity [5] . 11 Current SARS-CoV-2 vaccines target the viral spike protein, and anti-spike antibody levels are an 12 important correlate of vaccine efficacy [6] . Early studies are encouraging and suggest robust cellular and 13 humoral responses in the initial months following vaccination amongst LTCF residents, particularly in 14 previously-infected individuals [6, 7] . However, studies from the general population have reported 15 waning of antibody titres in the six months following vaccination, particularly in people older than 65 16 years [8] [9] [10] . We investigated quantitative anti-spike antibody titres amongst LTCF staff and residents in 17

England over the first nine months following second vaccination dose. 18 recorded. Only individuals with data on demographic characteristics and vaccinations were included in 11 this analysis and most could also be linked to full testing history (Appendix S1). An index value ≥0.8 defined Abbott anti-nucleocapsid assay positivity [13] . A threshold of 1200 AU/mL 21 was used for MSD anti-nucleocapsid assay, which had a specificity of 96% (48/50) using pre-pandemic 22 blood samples. 23

Log10-transformed MSD anti-spike levels were modelled using linear mixed effects models. Time was 4 centred at 21 days after second vaccine dose, with random intercept and slope terms for each 5 participant. This approach allows for the analysis of all available data within a single statistical model 6 and can accommodate irregular numbers and timings of measurements for each participant. Intercept 7 terms from the model correspond to estimated peak antibody levels and slope terms correspond to rate 8 of decline over time on the log-scale. 9

An initial model was fitted with independent effects assumed for vaccine type, sex, staff/resident status 10 and prior SARS-CoV-2 infection, followed by a model with interaction terms between vaccine type and 11 each other variable. The interaction model, allowing different effects by vaccine type, was found to provide better fit to the 5 data than the simpler independent effects model (P=0.01, likelihood ratio test (LRT)), and a further 6 improvement was found by adding age as linear predictor of peak antibody levels and slope (P=0.03, 7 LRT). 8

Based on findings from the mixed-effects model, peak antibody titres were greater in Pfizer-B recipients 9 than in Oxford-AZ recipients (×7.9, 95%CI 3.6-17.0; P<0.01), although we also observed a steeper annual 10 decline in this group (×0.08 at 12 months vs equivalent decline from peak, 0.01-0.72; P=0.02) ( Table 1 , 11 Figure 1 ). Prior infection with SARS-CoV-2 was associated with higher peak antibody levels and slower 12 decline for both Pfizer-B (peak ×2.8, 1.9-4.1; P<0.01) and Oxford-AZ (×4.8, 95%CI 3.2-7.1; P<0.01) 13 recipients. Male sex was associated with slightly higher peak in antibody levels for both vaccines (not 14 statistically significant) but steeper decline, particularly for Oxford-AZ recipients. LTCF resident vs staff 15 status was not associated with any statistically significant difference in peak antibody level or slope of 16 decline. However, increasing age was associated with lower antibody peak for Oxford-AZ recipients. 17 'Half-life' estimates of antibody decline were in the range 60-120 days for most subgroups, with values 18 >6 months in female Oxford-AZ recipients with prior infection, but 95% CIs were wide (Table S2) . Oxford-AZ they found peak antibody levels were higher in those with prior infection, and slightly lower 6 in males and younger ages. Peak antibody levels were greater in Pfizer-B recipients compared with 7

Oxford-AZ but were lower at older ages and for males[10]. 8

The collection of samples up to 9 months after vaccination allowed us to assess the rate of spike-specific 9 antibody decline from peak value. The mean half-life of antibody decline was reported as 85 days (95%CI 10 84-86) after Oxford-AZ in the CIS study, and this was increased to 131 days in those with prior infection. 11

They found comparable mean half-life after Pfizer-B of 101 days (100-102) which was extended to 188 12 days in those with prior infection [10] . Our data also revealed mean half-life in the range 60-120 days but 13 did not uncover significant variation in the rate of antibody decline between LTCF staff and residents. 14 Analysis of >8500 community-dwelling infection-naïve adults also found no difference in rates of waning 15 in donors aged ≥65 years although peak titres declined with age[9]. 16

Our study is consistent in finding higher peak levels and longer half-life associated with prior infection 17 for both vaccine types, and higher peak levels following Pfizer vaccination. However, we find no 18 difference between staff and residents besides a lower peak antibody response in older Oxford-AZ 19 recipients. The level of exposure to infection was much greater in LTCFs than in the community, [1] and 20 those residents who survived infection are likely to have more robust immunological responses to 21 vaccination than their community-dwelling peers who are included in studies of the general population. 22

Our study is limited by a modest sample size, so there is uncertainty regarding the presence and 3 magnitude of observed effects. It is also possible that some individuals labelled as infection-naïve may 4 have waned below the positivity threshold following infection early in the pandemic [15] . To account for 5 this, we used a lower Abbott positivity threshold and included MSD results in defining "prior-exposure", 6 but we cannot determine the chronology of infection in anti-nucleocapsid antibody positive participants. 7

As the analysis was carried out over a period of relatively low community transmission, it is unlikely that 8 antibody titres have been boosted by undetected breakthrough infections following second dose 9

vaccination. Finally, we have only described humoral responses to vaccination; analyses in LTCF staff 10 and residents of vaccine-induced cellular immune responses and functional measures of immunity such 11 as neutralization antibody titres are underway by our group and others. 12

Insights into the magnitude and duration of vaccine-induced immune responses are crucial to inform the 13 timing of booster vaccination, particularly with the emergence of novel variants such as Omicron. Our 14 findings reveal that current COVID-19 vaccines retain high immunogenicity in the LTCF setting but 15 factors such as peak antibody response and rate of antibody waning, which will be used to guide the 16 need for future vaccinations, are strongly influenced by vaccine regimen and prior infection status. 17

Ongoing assessment of humoral immunity will be important in order to guide introduction of optimal 18 booster regimens that maintain immunity over the longer term. 19

Acknowledgements 20

We thank the staff and residents in the LTCFs that participated in this study and Mark Marshall at NHS 21

England who pseudonymised the electronic health records. This work is independent research funded 22 by the Department of Health and Social Care (COVID-19 surveillance studies). MK is funded by a 23 regression fits from a statistical model (omitting age and sex) to estimate trends in each group. 5

De-identified test results and limited metadata will be made available for use by researchers in future 7 studies, subject to appropriate research ethical approvals once the VIVALDI study cohort has been 8 finalised. These datasets will be accessible via the Health Data Research UK Gateway. 

Surveillance data from public online national reports on COVID-19 in long-term care facilities

Vaccine update: issue 315

Vaccine effectiveness and duration of protection of Comirnaty

Vaxzevria and Spikevax against mild and severe COVID-19 in the UK

Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and

Oxford-AstraZeneca vaccines by previous infection status

Relationships Between Age, Frailty, Length of Care Home 11 Residence and Biomarkers of Immunity and Inflammation in Older Care Home Residents in the United 12

Correlates of protection against symptomatic and asymptomatic

SARS-CoV-2 infection

Immunogenicity of single vaccination with BNT162b2 or ChAdOx1 nCoV-16 19 at 5-6 weeks post vaccine in participants aged 80 years or older: an exploratory analysis

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine 19 over 6 Months

Waning of SARS-CoV-2 antibodies targeting the Spike 21 protein in individuals post second dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and risk of 22 breakthrough infections: analysis of the Virus Watch community cohort

SARS-CoV-2 anti-spike IgG antibody responses after second dose 25 of ChAdOx1 or BNT162b2 and correlates of protection in the UK general population